Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Kidney Cancer treatment details. Immunotherapy. Université de Lyon, Centre Léon Bérard, Medical Oncology Department, Institut National de la Sante et de la Recherche Medicale , Lyon Cedex , France



Survival: 33.0 months
   
Toxicity Grade: 4
   
Treatments: Immunotherapy
   
Drugs:
Country: France
   
City/State/Province: Lyon Cedex
   
Hospital: Université de Lyon, Centre Léon Bérard, Medical Oncology Department, Institut National de la Sante et de la Recherche Medicale
   
Journal: Link
   
Date: 9/2008

Description:
Patients: This study involved 155 patients with metastatic renal cell (kidney) cancer. The median age was 55, ranging from 25 to 74 years old. The majority of patients were men (82%).

Treatment: Patients were treated with immunological therapy, substances that exist in the body normally and influence the immune system function. Patients were given interleukin-2 (IL-2) and interferon-alpha (IFN-a). About half of the patients received IL-2 intravenously (through a vein), and the others received the IL-2 through an injection beneath the skin (subcutaneous).

Toxicity: Grade 3 and 4 toxicities occurred in 85.9% of the patients receiving the intravenous IL-2, and in 74.4% of the patients receiving the subcutaneous IL-2. Grade 3 and 4 toxicities included fever (without infection), hypotension (low blood pressure), vomiting, diarrhea, nausea, neurological toxicity, anxiety, and increased creatinine levels.

Results: The median overall survival was 33 months for all patients. For those receiving the intravenous IL-2, the median survival was 37.7 months, and for those receiving IL-2 subcutaneously, it was 30.1 months. There was not a statistically significant difference between survival in the two treatment groups.

Support: This study was supported by research funds from Roche France and Chiron France.

Correspondence: Dr. Sylvia Negrier

E-mail to a Friend Email Physician More Information